LLY · BEAM 10-KFeb 24 '26
“In October 2023, we entered into a Transfer and Delegation Agreement, or the Lilly Agreement, with Eli Lilly and Company, or Lilly, pursuant to which Lilly acquired certain assets and other rights under the Verve Agreement, including our opt-in rights to co-develop and co-commercialize Verve's base editing programs for cardiovascular disease.”
PFE · BEAM 10-KFeb 24 '26
“In December 2021, we entered into a four-year research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system.”
LLY · NKTR 10-KMar 13 '26
“In the past, we have received a number of significant payments from collaboration agreements and other significant transactions, including $1.9 billion in total consideration received under our arrangement with BMS, development cost reimbursements from BMS, and a $150.0 million upfront payment from Eli Lilly and Company for our collaboration agreement for rezpegaldesleukin.”
PFE · NKTR 10-KMar 13 '26
“Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.”
LLY · ZURA 10-KMar 19 '26
“On April 26, 2023, our consolidated subsidiary ZB17 LLC ("ZB17") entered into a license agreement with Lilly (the "2023 Lilly License" and, together with the 2022 Lilly License (as defined below), the "Lilly Licenses"), for an exclusive license to develop, manufacture and commercialize tibulizumab.”
PFE · ZURA 10-KMar 19 '26
“license agreement with Pfizer under which we were granted rights to certain patents, know-how and technology that are important and necessary to our business, including for crebankitug.”